BiotechTube

Ianalumab + Placebo

Phase 3Active
1 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Autoimmune Hemolytic Anemia (wAIHA)

Conditions

Warm Autoimmune Hemolytic Anemia (wAIHA)

Trial Timeline

Dec 30, 2022 → Dec 19, 2028

NCT ID
NCT05648968

About Ianalumab + Placebo

Ianalumab + Placebo is a phase 3 stage product being developed by Novartis for Warm Autoimmune Hemolytic Anemia (wAIHA). The current trial status is active. This product is registered under clinical trial identifier NCT05648968. Target conditions include Warm Autoimmune Hemolytic Anemia (wAIHA).

What happened to similar drugs?

0 of 5 similar drugs in Warm Autoimmune Hemolytic Anemia (wAIHA) were approved

Approved (0) Terminated (1) Active (4)
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Obexelimab + ObexelimabZenas BioPharmaPhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT05624749Phase 3Active
NCT05639114Phase 3Active
NCT05648968Phase 3Active

Competing Products

12 competing products in Warm Autoimmune Hemolytic Anemia (wAIHA)

See all competitors
ProductCompanyStageHype Score
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
APL-2Apellis PharmaceuticalsPhase 2
29
Obexelimab + ObexelimabZenas BioPharmaPhase 3
38
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34